A review of the pathophysiologic features of early type 2 diabetes mellitus, the benefits of early glycemic control, the concerns of patients that may influence treatment adherence, and how the use of newer treatment options are addressed.
Conclusion
Given the multifactorial nature of diabetes pathophysiology, early combination therapy incorporating agents with different mechanisms of action is advocated. Medication side effects and risks influence patients’ treatment choices. These concerns include hypoglycemia, weight gain, and fears of treatment failure. With the increasing complexity of therapy regimens for diabetes, the role of diabetes educators includes recommending therapy, counseling about adverse effects, monitoring for contraindications, identifying therapeutic duplication, as well as discussion of new agents to optimize patient outcomes. A case study is used to describe the process of choosing well-tolerated therapies at first diagnosis.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services; 2011.
2.
LowJCFelnerEIMuirAB. Do obese children with diabetic ketoacidosis have type 1 or type 2 diabetes?Prim Care Diabetes. 2012;6(1):61-65.
3.
BadaruAPihokerC. Type 2 diabetes in childhood: clinical characteristics and role of β-cell autoimmunity. Curr Diab Rep. 2012;12(1):75-81.
4.
GarberAJHandelsmanYEinhornD. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-946.
5.
HolmanRRPaulSKBethelMA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
6.
PratleyREWeyerC. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44:929-945.
7.
WeyerCTataranniPABogardusCPratleyRE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
8.
BrownJBConnerCNicholsGA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501-506.
9.
KellowNJSavigeGSKhalilH. Predictors of poor glycaemic control during the initial five years post-diagnosis in rural adults with type 2 diabetes. Aust J Rural Health. 2011;19(5):267-274.
10.
KahnSELachinJMZinmanB. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552-1560.
11.
NathanDMBuseJBDavidsonMB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
12.
RodbardHWJellingerPS. The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm. Diabetologia. 2010;53:2458-2460.
13.
RodbardHWJellingerPS. Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes. JAMA. 2010;304:405-406.
14.
ZinmanB. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?Am J Med. 2011;124(1)(suppl):S19-S34.
15.
HolstJJSeinoY. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes. Diabetes Res Clin Pract. 2009;85:1-3.
16.
KnopFKVilsbøllTMadsbadSHolstJJKrarupT. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007;50:797-805.
17.
GarberAJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34(suppl 2):S258-S263.
18.
MariADegnKBrockBRungbyJFerranniniESchmitzO. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30:2032-2033.
19.
DegnKBJuhlCBSturisJ. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-1194.
20.
MarreMShawJBrandleM. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
21.
NauckMFridAHermansenK. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
22.
GarberAHenryRRatnerR. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
23.
ZinmanBHoogwerfBJDurán GarcíaS. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485.
24.
BuseJBHenryRRHanJ. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
25.
DeFronzoRARatnerREHanJKimDDFinemanMSBaronAD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
26.
PeyrotMSkovlundSELandgrafR. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009;25:1985-1993.
27.
PeyrotMRubinRRLauritzenT. Patient and provider perceptions of care for diabetes: results of the cross-national DAWN Study. Diabetologia. 2006;49:279-288.
28.
HuangESBrownSEThakurN. Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes. Diabetes Care. 2009;32:311-316.
29.
HauberABMohamedAFJohnsonFRFalveyH. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26:416-424.
30.
BlevinsTHanJNicewarnerDChenSOliveiraJHAronoffS. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med. 2010;122:118-128.
31.
Russell-JonesDVaagASchmitzO. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52: 2046-2055.
32.
GallwitzBVaagAFalahatiAMadsbadS. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract. 2010;64:267-276.
33.
ParksMRosebraughC. Weighing risks and benefits of liraglutide: the FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010;362:774-777.
